Eton Pharmaceuticals (NASDAQ:ETON) Reaches New 1-Year High - What's Next?

Key Points

• Eton Pharmaceuticals reached a new 52-week high of $63.83, with shares last trading at $61.48 and the company valued at approximately $1.76 billion.
• Analyst sentiment is mixed: four analysts rate the stock a Buy and two rate it a Sell, resulting in a consensus Hold rating and an average price target of $67.50.
• The company exceeded quarterly expectations, reporting $0.43 in earnings per share versus a $0.19 estimate and revenue of $37.59 million versus $27.11 million expected; meanwhile, insiders sold 150,000 shares worth about $4.85 million over the prior quarter.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $63.83 and last traded at $61.48, with a volume of 608776 shares changing hands. The stock had previously closed at $63.43.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. B. Riley Financial reissued a "buy" rating and set a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Wall Street Zen raised shares of Eton Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 13th. Zacks Research downgraded shares of Eton Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Monday, July 13th. Canaccord Genuity Group boosted their price objective on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a "buy" rating in a report on Friday, August 14th. Finally, Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, July 28th. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $67.50.

Eton Pharmaceuticals Stock Performance

The stock has a 50-day simple moving average of $40.97 and a 200-day simple moving average of $29.68. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 161.79 and a beta of 0.86. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.24. The business had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. On average, analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.67 earnings per share for the current year.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, Director Jennifer Mckie Adams sold 50,000 shares of the firm's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company's stock, valued at $1,624,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Krempa sold 42,797 shares of the business's stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the completion of the sale, the insider directly owned 25,249 shares of the company's stock, valued at $843,064.11. The trade was a 62.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 150,000 shares of company stock worth $4,853,921 over the last quarter. 16.49% of the stock is currently owned by insiders.

Institutional Trading of Eton Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ETON. Quarry LP bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth about $37,000. Legal & General Group Plc bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $41,000. Toth Financial Advisory Corp bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $43,000. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth about $44,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Eton Pharmaceuticals in the fourth quarter worth about $74,000. Institutional investors own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source